136 related articles for article (PubMed ID: 35082924)
1. Real-world evidence of the management and prognosis of young women (⩽40 years) with
Mallet A; Lusque A; Levy C; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; De La Motte Rouge T; Faure C; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Cottu P; Dalenc F; Petit T; Payen O; Uwer L; Guiu S; Frenel JS
Ther Adv Med Oncol; 2022; 14():17588359211070362. PubMed ID: 35082924
[TBL] [Abstract][Full Text] [Related]
2. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
5. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
6. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
7. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
8. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
13. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
[TBL] [Abstract][Full Text] [Related]
14. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
Dalenc F; Lusque A; De La Motte Rouge T; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; Levy C; Uwer L; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Frenel JS; Petit T; Chevrot M; Bachelot T; Guiu S
Eur J Cancer; 2022 Mar; 164():70-79. PubMed ID: 35176614
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
Annonay M; Gauquelin L; Geiss R; Ung M; Cristol-Dalstein L; Mouret-Reynier MA; Goncalves A; Abadie-Lacourtoisie S; Francois E; Perrin C; Le Fel J; Lorgis V; Servent V; Uwer L; Jouannaud C; Leheurteur M; Joly F; Campion L; Courtinard C; Villacroux O; Petit T; Soubeyran P; Terret C; Bellera C; Brain E; Delaloge S
Breast; 2021 Dec; 60():138-146. PubMed ID: 34624756
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
17. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Bertho M; Fraisse J; Patsouris A; Cottu P; Arnedos M; Pérol D; Jaffré A; Goncalves A; Lebitasy MP; D'Hondt V; Dalenc F; Ferrero JM; Levy C; Dabakuyo S; Rouzier R; Penault-Llorca F; Uwer L; Eymard JC; Breton M; Chevrot M; Thureau S; Petit T; Simon G; Frénel JS
Ther Adv Med Oncol; 2021; 13():1758835920987657. PubMed ID: 33613700
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer.
Shin J; Kim JY; Oh JM; Lee JE; Kim SW; Nam SJ; Park W; Park YH; Ahn JS; Im YH
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835414
[TBL] [Abstract][Full Text] [Related]
19. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]